Case study: Identifying allosteric modulators for GPCRs
Posted: 25 January 2021 | Eurofins Discovery | 1 comment
Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.
The sheer number of understudied and orphan receptors in the GPCR family have made them an attractive target for many drug discovery programs. These targeted clinical candidates have the potential to minimize side-effects associated with unbiased orthosteric GPCR activation. Developing methods to measure signaling bias has proven to be a major barrier in the development of new GPCR therapies – a barrier that Eurofins Discovery has actively worked to deconstruct.
Related content from this organisation
- SAFIRE: AI predicted ADME for drug discovery: leveraging bioprint
- Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
- SH2 domains as a target class in cancer and inflammation
- Cardiac and vascular safety liabilities using totality of evidence approach
- Decoding cancer and inflammation: identifying selective inhibitors of SH2 domains
Related topics
Assays, Biopharmaceuticals, Drug Discovery, Hit-to-Lead, Imaging, Screening, Targets
Related organisations
Eurofins Discovery
GPCRs have been highly understudied in the context of COVID-19 and given that they are cell surface receptors and the COVID-19 S (spike) protein has been implicated in invasion/pathogenesis and therapeutic poor response, it will be interesting to understnad the interaction between GPCRs and COVID-19 as well as in relation to other pathogens that may be drivers of infection in COVID cases such as other coronaviruses/respiratory and non respiratory pathogens.